These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 16518378)

  • 1. Success in translational research: lessons from the development of bortezomib.
    Sánchez-Serrano I
    Nat Rev Drug Discov; 2006 Feb; 5(2):107-14. PubMed ID: 16518378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translational research in the development of bortezomib: A core model.
    Sanchez-Serrano I
    Discov Med; 2005 Dec; 5(30):527-33. PubMed ID: 20704835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Closing the gap.
    Nat Rev Drug Discov; 2006 Feb; 5(2):89. PubMed ID: 16521323
    [No Abstract]   [Full Text] [Related]  

  • 4. [Pharmacological and clinical profile of Bortezomib (Velcade)].
    Fujii H; Kotobuki Y; Nomura S; Harada Y
    Nihon Yakurigaku Zasshi; 2007 Nov; 130(5):421-9. PubMed ID: 18000359
    [No Abstract]   [Full Text] [Related]  

  • 5. Captivating bortezomib: an active but still mysterious drug.
    Di Raimondo F; Conticello C
    Leuk Res; 2010 Apr; 34(4):411-2. PubMed ID: 19819547
    [No Abstract]   [Full Text] [Related]  

  • 6. "Development of the proteasome inhibitor Velcade (Bortezomib)" by Julian Adams, Ph.D., and Michael Kauffman, M.D., Ph.D.
    Bold R
    Cancer Invest; 2004; 22(2):328-9. PubMed ID: 15199617
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecule of the month. Bortezomib.
    Drug News Perspect; 2003 Jun; 16(5):324. PubMed ID: 12942163
    [No Abstract]   [Full Text] [Related]  

  • 8. Velcade displays promising activity in primary effusion lymphoma cells.
    McConkey D; Nawrocki ST; Andtbacka R
    Cancer Biol Ther; 2005 Apr; 4(4):491-2. PubMed ID: 15908793
    [No Abstract]   [Full Text] [Related]  

  • 9. [Situation of translational research and development of molecular-targeted agents for multiple myeloma].
    Kizaki M
    Nihon Rinsho; 2007 Dec; 65(12):2357-61. PubMed ID: 18069283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology, pharmacokinetics, and practical applications of bortezomib.
    Schwartz R; Davidson T
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):14-21. PubMed ID: 15688598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of bortezomib in B-cell non-Hodgkin's lymphoma.
    Wang M; Zhou Y; Zhang L; Nguyen CA; Romaguera J
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):983-91. PubMed ID: 16831071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib: a novel therapy approved for multiple myeloma.
    Richardson PG; Anderson KC
    Clin Adv Hematol Oncol; 2003 Oct; 1(10):596-600. PubMed ID: 16258456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor-κB activity in human oral cancer cells.
    Tamatani T; Takamaru N; Hara K; Kinouchi M; Kuribayashi N; Ohe G; Uchida D; Fujisawa K; Nagai H; Miyamoto Y
    Int J Oncol; 2013 Mar; 42(3):935-44. PubMed ID: 23340716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
    Leonard JP; Furman RR; Coleman M
    Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bortezomib (Velcade). Laboratory: Millenium Pharmaceuticals Inc].
    Moreno Alvarez PJ
    Farm Hosp; 2003; 27(4):274-5. PubMed ID: 12966459
    [No Abstract]   [Full Text] [Related]  

  • 16. Inhibition of bortezomib-induced apoptosis by red blood cell uptake.
    Wheat LM; Kohlhaas SL; Monbaliu J; De Coster R; Majid A; Walewska RJ; Dyer MJ
    Leukemia; 2006 Sep; 20(9):1646-9. PubMed ID: 16791268
    [No Abstract]   [Full Text] [Related]  

  • 17. Bortezomib for previously untreated multiple myeloma.
    Delforge M
    Expert Opin Pharmacother; 2011 Nov; 12(16):2553-64. PubMed ID: 21942881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Proteasome inhibitor bortezomib as an anticancer drug].
    Yasui H; Hideshima T
    Tanpakushitsu Kakusan Koso; 2006 Aug; 51(10 Suppl):1251-6. PubMed ID: 16922383
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug pricing: No cure, no cost.
    Jack A
    BMJ; 2007 Jul; 335(7611):122-3. PubMed ID: 17641343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib data show improved survival in patients with relapsed multiple myeloma.
    Oncology (Williston Park); 2004 Aug; 18(9):1199, 1201. PubMed ID: 15471202
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.